|
1
|
Liu X, Ren Z, Xu Y, Sun W, Li Y, Rui X, Xie D, Meng X, Zheng Z. Establishment and characterization of novel human primary endometrial cancer cell line (ZJB-ENC1) and its genomic characteristic. J Cancer 2019; 10:6466-6474. [PMID: 31772679 PMCID: PMC6856739 DOI: 10.7150/jca.33013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Accepted: 08/26/2019] [Indexed: 12/12/2022] Open
Abstract
The establishment of human malignant tumor cell lines can provide abundant experimental materials for understanding the biological characteristics of tumors, studying the carcinogenesis, molecular genetics and the mechanism of metastasis and evolution. In this study, a novel cell line designated ZJB-ENC1 has been established from poorly differentiated endometrioid adenocarcinoma. Cytological results showed monolayer-cultured cells were polygonal in shape and a piling-up tendency without contact inhabitation. Immunohistochemistry analysis showed that the cells were negative for ER, PR, c-erbB2, E-CAD, CD117, and OCT3/4, but strongly positive for PTEN and P16. Meanwhile, the tumorigenicity of ZJB-ENC1 was confirmed by subcutaneous transplantation of the cells into a xenograft mouse model. In addition, the results of the whole exome sequencing revealed a unique genomic characteristic of ZJB-ENC1 cells, all common and novel SNPs and InDels were identified. In conclusion, this new stable cell line may promote basic and clinical research on endometrial cancer (EC).
Collapse
Affiliation(s)
- Xiaozhen Liu
- Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China.,The Experimental Center, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, 310022, China.,The Experimental Center, Zhejiang cancer hospital , Hangzhou, 310022, China
| | - Zhuozhuo Ren
- Medical Support Department, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou 310022, China
| | - Yu Xu
- Department of Hematology, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, 310022, China
| | - Wei Sun
- Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China.,The Experimental Center, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, 310022, China.,The Experimental Center, Zhejiang cancer hospital , Hangzhou, 310022, China
| | - Yongfeng Li
- Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China.,Department of Breast Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, 310022, China.,Department of Breast Surgery, Zhejiang cancer hospital, Hangzhou, 310022, China
| | - Xinmiao Rui
- The Second Clinical Department, Zhejiang Chinese Medical University, Hangzhou, 310022, China
| | - Dafei Xie
- General Surgery Department, Zhejiang Hospital, Hangzhou, 310022, China
| | - Xuli Meng
- Department of Breast Thyroid Surgery, Tongde Hospital of Zhejiang Province, Hangzhou, 310022, China
| | - Zhiguo Zheng
- Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, 310022, China.,The Experimental Center, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, 310022, China.,The Experimental Center, Zhejiang cancer hospital , Hangzhou, 310022, China
| |
Collapse
|